179 related articles for article (PubMed ID: 22020329)
1. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
[TBL] [Abstract][Full Text] [Related]
2. Preneoplastic changes persist after IGF-IR downregulation and tumor regression.
Jones RA; Petrik JJ; Moorehead RA
Oncogene; 2010 Aug; 29(34):4779-86. PubMed ID: 20543862
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells.
Saleh S; Thompson DE; McConkey J; Murray P; Moorehead RA
BMC Cancer; 2016 Jun; 16():359. PubMed ID: 27282619
[TBL] [Abstract][Full Text] [Related]
4. Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice.
Watson KL; Moorehead RA
BMC Cancer; 2013 Aug; 13():375. PubMed ID: 23919516
[TBL] [Abstract][Full Text] [Related]
5. IGF-IR mediated mammary tumorigenesis is enhanced during pubertal development.
Jones RA; Watson KL; Campbell CI; Moorehead RA
PLoS One; 2014; 9(9):e108781. PubMed ID: 25259518
[TBL] [Abstract][Full Text] [Related]
6. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation.
Jones RA; Campbell CI; Gunther EJ; Chodosh LA; Petrik JJ; Khokha R; Moorehead RA
Oncogene; 2007 Mar; 26(11):1636-44. PubMed ID: 16953219
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Prat A; Karginova O; Parker JS; Fan C; He X; Bixby L; Harrell JC; Roman E; Adamo B; Troester M; Perou CM
Breast Cancer Res Treat; 2013 Nov; 142(2):237-55. PubMed ID: 24162158
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
9. Murine mammary tumor cells with a claudin-low genotype.
Campbell CI; Thompson DE; Siwicky MD; Moorehead RA
Cancer Cell Int; 2011 Aug; 11():28. PubMed ID: 21846397
[TBL] [Abstract][Full Text] [Related]
10. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.
Xu K; Usary J; Kousis PC; Prat A; Wang DY; Adams JR; Wang W; Loch AJ; Deng T; Zhao W; Cardiff RD; Yoon K; Gaiano N; Ling V; Beyene J; Zacksenhaus E; Gridley T; Leong WL; Guidos CJ; Perou CM; Egan SE
Cancer Cell; 2012 May; 21(5):626-641. PubMed ID: 22624713
[TBL] [Abstract][Full Text] [Related]
11. High levels of dietary soy decrease mammary tumor latency and increase incidence in MTB-IGFIR transgenic mice.
Watson KL; Stalker L; Jones RA; Moorehead RA
BMC Cancer; 2015 Feb; 15():37. PubMed ID: 25655427
[TBL] [Abstract][Full Text] [Related]
12. Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.
Campbell CI; Moorehead RA
BMC Cancer; 2011 Nov; 11():480. PubMed ID: 22070644
[TBL] [Abstract][Full Text] [Related]
13. Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.
Linnerth NM; Siwicky MD; Campbell CI; Watson KL; Petrik JJ; Whitsett JA; Moorehead RA
Neoplasia; 2009 Jul; 11(7):672-82. PubMed ID: 19568412
[TBL] [Abstract][Full Text] [Related]
14. Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
Hoenerhoff MJ; Shibata MA; Bode A; Green JE
Transgenic Res; 2011 Apr; 20(2):247-59. PubMed ID: 20549348
[TBL] [Abstract][Full Text] [Related]
15. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
[TBL] [Abstract][Full Text] [Related]
16. Re-expression of miR-200c suppresses proliferation, colony formation and in vivo tumor growth of murine claudin-low mammary tumor cells.
Jones R; Watson K; Bruce A; Nersesian S; Kitz J; Moorehead R
Oncotarget; 2017 Apr; 8(14):23727-23749. PubMed ID: 28423599
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 expression is elevated in claudin-low mammary tumor cells.
Thompson DE; Siwicky MD; Moorehead RA
Cancer Cell Int; 2012 Feb; 12():6. PubMed ID: 22356861
[TBL] [Abstract][Full Text] [Related]
18. Inducible expression of dominant negative insulin-like growth factor I receptor in MCF-7 breast cancer cells.
Modha G; Blanchard A; Sidorchuk J; Venditti M; Shiu R; Myal Y
Endocrine; 2003 Dec; 22(3):293-303. PubMed ID: 14709803
[TBL] [Abstract][Full Text] [Related]
19. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
[TBL] [Abstract][Full Text] [Related]
20. The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis.
Jones RA; Moorehead RA
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):407-13. PubMed ID: 19002570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
